Oxford Pharmaceutical Resources, Inc. Report issue

For profit Phase 2 Phase 3
Founded: Totowa NJ United States (1989)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2007
NCT00527319
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

phenazopyridine (gantanol) (1 trial)

Drugs in Phase 2 Trials (2)

etodolac (lodine) (1 trial)

propranolol (inderal) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 2)

Infections (Phase 3)

Urinary Tract Infections (Phase 3)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3